CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
cyproterone acetate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00849082
NCT00849082Phase 3Completed

Phase III Randomized Comparison of Pelvic Radiotherapy Alone vs Pelvic Radiotherapy Plus the LHRH Analogue Goserelin and Cyproterone Acetate in Carcinoma of the Prostate at High Risk for Metastasis

European Organisation for Research and Treatment of Cancer - EORTC·interventional·Posted Feb 23, 2009·Updated Jul 11, 2012

In Brief

A Phase 3 clinical trial evaluating cyproterone acetate, goserelin acetate, and 1 other intervention for Prostate Cancer. Completed.

Detailed Summary

RATIONALE: Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective treatment for prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin and cyproterone, may lessen the amount of androgens made by the body and reduces the amount of androgens available to the body. It is not yet know whether radiation therapy alone is more effective than radiation therapy given together with goserelin and cyproterone in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared to giving radiation therapy together with goserelin and cyproterone in treating patients with prostate cancer that is at high risk for metastasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 23, 2009
Enrollment StartMay 1, 1987
Primary CompletionNov 1, 1995
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 17.4 years ago

Interventions

cyproterone acetatedrug

goserelin acetatedrug

radiation therapyradiation